William Harnisch’s Neurocrine Biosciences NBIX Stock Holding History

William Harnisch’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-900	Closed	-$110K	–	63
2020 Q2	$110K	Hold	900	–	–	0.03%	43
2020 Q1	$78K	Hold	900	–	–	0.03%	38
2019 Q4	$97K	Buy	+900	New	+$94.2K	0.02%	56
2017 Q3	–	Sell	-33,000	Closed	-$1.52M	–	55
2017 Q2	$1.52M	Buy	+33,000	New	+$1.6M	0.24%	30

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

William Harnisch's NBIX Position: Q3 2020 in Review

William Harnisch sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 900 shares — an estimated $110K sold.

William Harnisch first reported a position in NBIX in Q2 2017 and held it in 4 quarters. The position peaked at $1.52M in Q2 2017. 419 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

William Harnisch reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
William Harnisch sold 900 Neurocrine Biosciences shares in Q3 2020, an estimated $110K.
William Harnisch first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 4 quarters.
William Harnisch's Neurocrine Biosciences position peaked at $1.52M in Q2 2017.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Peconic Partners's 13F filing for Q3 2020, filed 16 Nov 2020.